कंपनी का अवलोकन
AEON Biopharma, Inc. operates as a clinical stage biopharmaceutical entity dedicated to the research and development of botulinum toxins, with a primary focus on creating ABP-450 (prabotulinumtoxinA) injections designed to address debilitating medical conditions such as cervical dystonia. The company functions within the broader Healthcare sector, specifically inside the Biotechnology industry, which generally involves high-risk, high-reward development cycles focused on innovative drug therapies before regulatory approval. Currently, the organization maintains a market capitalization of $21.00M and employs a workforce of 8 individuals to execute its development pipeline. The modest market cap of $21.00M, combined with the absence of reported annual revenue figures in the provided data, indicates that the company remains in a pre-commercialization or early-stage operational phase where value is derived from intellectual property and pipeline progress rather than current sales volume.
वित्तीय स्वास्थ्य
The financial performance of AEON Biopharma, Inc. over the trailing twelve months (TTM) reflects a significant operational deficit, with Net Income standing at $-39,222,000 and EBITDA recorded at $-16,224,000. While specific revenue figures are not listed in the available data, the substantial negative net income relative to the reported EBITDA suggests a cost structure heavily weighted toward operating expenses such as research, development, and administrative overhead that exceed gross earnings. The company's Free Cash Flow is reported at $-10,995,750, which signifies a negative cash conversion where cash outflows for capital expenditures and working capital changes further deplete liquid assets. Regarding profitability metrics, the Gross Margin, Operating Margin, and Profit Margin are all recorded at 0.0%, a common characteristic in early-stage biotechnology firms where no commercial sales have yet been recognized or where revenue does not cover the direct costs of goods sold. On the balance sheet, the company holds $3.01M in cash against total debt obligations of $35.74M, resulting in a Debt to Equity ratio that is not applicable (N/A) due to the lack of shareholder equity data, indicating a highly leveraged position relative to liquid assets. The Current Ratio stands at 0.49, which explicitly indicates that the company's current liabilities exceed its current assets, signaling potential short-term liquidity constraints. Furthermore, the Return on Equity (ROE) is listed as N/A, while the Return on Assets (ROA) is calculated at -234.2%, revealing that the management's utilization of total assets has resulted in a severe negative return on the capital base during this period.
मूल्यांकन आकलन
Valuation multiples for AEON Biopharma, Inc. present a mixed picture typical of unprofitable clinical-stage entities. The Trailing Twelve Months (TTM) P/E Ratio is listed as N/A due to negative earnings, whereas the Forward P/E is reported at -1.20, implying that the market expects continued negative earnings or a specific accounting scenario for the upcoming period rather than profitable growth. The Price to Book ratio is recorded at -0.18, a negative figure that indicates the market capitalization is valued below the company's net asset book value, suggesting a distressed or speculative valuation rather than a traditional premium. Alternative valuation metrics such as the Price to Sales ratio and EV/EBITDA are also negative or unavailable, with the EV/EBITDA standing at -3.31, reinforcing that standard valuation models relying on profitability or sales multiples are not applicable in their conventional form. The stock's recent price volatility is captured by its 52-week trading range, which spans from a low of $0.38 to a high of $1.45. Without a specific current price provided in the facts, the trading range defines the historical volatility envelope within which the security has fluctuated over the last year. The Beta is reported at 0.73, indicating that the stock's price movements are less volatile than the broader market index, moving at approximately 27% less intensity than the overall market average during periods of fluctuation.
Growth & Income
The growth trajectory of AEON Biopharma, Inc. is characterized by a lack of historical financial data for comparison, as both Revenue Growth (YoY) and Earnings Growth (YoY) are listed as N/A. In the absence of positive earnings or revenue streams, the concept of earnings growing faster or slower than revenue is not applicable, as the company is still in a phase of investment rather than expansion. The company does not pay dividends to shareholders, evidenced by a Dividend Yield of N/A and a Payout Ratio of 0.0%, which means the organization reinvests all available resources, however limited, back into its clinical development programs and operational costs. This non-dividend profile is standard for biotechnology firms in the clinical stage, where capital preservation and pipeline advancement take precedence over income distribution to investors. Consequently, the overall growth and income profile for AEON Biopharma, Inc. is defined entirely by its potential future commercialization of ABP-450 rather than current financial performance or shareholder yield.